[go: up one dir, main page]

NO20010292D0 - Anvendelse av glukose-opptaks-enhancer for redusering av apoptose - Google Patents

Anvendelse av glukose-opptaks-enhancer for redusering av apoptose

Info

Publication number
NO20010292D0
NO20010292D0 NO20010292A NO20010292A NO20010292D0 NO 20010292 D0 NO20010292 D0 NO 20010292D0 NO 20010292 A NO20010292 A NO 20010292A NO 20010292 A NO20010292 A NO 20010292A NO 20010292 D0 NO20010292 D0 NO 20010292D0
Authority
NO
Norway
Prior art keywords
glucose uptake
reduce apoptosis
uptake enhancer
enhancer
apoptosis
Prior art date
Application number
NO20010292A
Other languages
English (en)
Other versions
NO20010292L (no
Inventor
Antoine Michel Alain Bril
Robin Edwin Buckingham
Nassirah Khandoudi
Original Assignee
Smithkline Beecham Plc
Smithkline Beecham Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9815871.0A external-priority patent/GB9815871D0/en
Priority claimed from GBGB9815872.8A external-priority patent/GB9815872D0/en
Priority claimed from GBGB9905387.8A external-priority patent/GB9905387D0/en
Application filed by Smithkline Beecham Plc, Smithkline Beecham Lab filed Critical Smithkline Beecham Plc
Publication of NO20010292D0 publication Critical patent/NO20010292D0/no
Publication of NO20010292L publication Critical patent/NO20010292L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20010292A 1998-07-21 2001-01-18 Anvendelse av glukose-opptaks-enhancer for redusering av apoptose NO20010292L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9815871.0A GB9815871D0 (en) 1998-07-21 1998-07-21 Novel compound
GBGB9815872.8A GB9815872D0 (en) 1998-07-21 1998-07-21 Novel method
GBGB9905387.8A GB9905387D0 (en) 1999-03-09 1999-03-09 Novel method
PCT/GB1999/002361 WO2000004890A1 (en) 1998-07-21 1999-07-21 Use of glucose uptake enhancer for reducing apoptosis

Publications (2)

Publication Number Publication Date
NO20010292D0 true NO20010292D0 (no) 2001-01-18
NO20010292L NO20010292L (no) 2001-03-08

Family

ID=27269407

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20010292A NO20010292L (no) 1998-07-21 2001-01-18 Anvendelse av glukose-opptaks-enhancer for redusering av apoptose

Country Status (25)

Country Link
EP (2) EP1516617A2 (no)
JP (1) JP2002521326A (no)
KR (1) KR20010079551A (no)
CN (1) CN1310620A (no)
AP (1) AP2001002036A0 (no)
AT (1) ATE288746T1 (no)
AU (1) AU5053799A (no)
BG (1) BG105250A (no)
BR (1) BR9912117A (no)
CA (1) CA2338211A1 (no)
DE (1) DE69923687T2 (no)
DK (1) DK1098639T3 (no)
EA (1) EA200100165A1 (no)
ES (1) ES2237929T3 (no)
HU (1) HUP0103199A3 (no)
ID (1) ID26986A (no)
IL (1) IL140664A0 (no)
NO (1) NO20010292L (no)
OA (1) OA11579A (no)
PL (1) PL345627A1 (no)
PT (1) PT1098639E (no)
SI (1) SI1098639T1 (no)
SK (1) SK1012001A3 (no)
TR (1) TR200100207T2 (no)
WO (1) WO2000004890A1 (no)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3073700A (en) * 1999-01-19 2000-08-07 Sankyo Company Limited Troglitazone-containing medicinal compositions for inhibiting apoptosis
DK1206457T3 (da) * 1999-08-27 2004-02-16 Lilly Co Eli Biaryl-oxa(thia)zolderivater og deres anvendelse som modulatorer PPAP'ER

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0306228B1 (en) * 1987-09-04 1999-11-17 Beecham Group Plc Substituted thiazolidinedione derivatives
JPH05202042A (ja) * 1992-01-24 1993-08-10 Sankyo Co Ltd 糖尿病性合併症治療剤
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
NZ314406A (en) * 1996-03-18 2000-12-22 Sankyo Co Treatment or prophylaxis of pancreatitis with a medicament containing an insulin sensitiser including oxazoles and thiazoles
GB9611947D0 (en) * 1996-06-07 1996-08-07 Glaxo Group Ltd Medicaments
US6277819B1 (en) * 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
EP0958818A1 (en) * 1996-09-12 1999-11-24 Sankyo Company Limited Glutathione reductase activity potentiator containing troglitazone
GB9721692D0 (en) * 1997-10-13 1997-12-10 Smithkline Beecham Plc Novel treatment
EP1047423B1 (en) * 1997-11-19 2006-05-10 Takeda Pharmaceutical Company Limited Novel apoptosis inhibitors
WO1999043326A1 (en) * 1998-02-24 1999-09-02 The Trustees Of The University Of Pennsylvania Use of a cardiac purinoceptor to effect cellular glucose uptake
WO1999059586A1 (en) * 1998-05-19 1999-11-25 Regents Of The University Of California Thiazolidine and oxazolidine derivatives for the treatment of acute myocardial infarction and inhibition of cardiomyocyte apoptosis
US5968960A (en) * 1999-01-14 1999-10-19 The Regents Of The University Of California Use of thiazolidinediones to ameliorate the adverse consequences of myocardial ischemia on myocardial function and metabolism

Also Published As

Publication number Publication date
BR9912117A (pt) 2001-04-10
BG105250A (en) 2001-11-30
DE69923687D1 (de) 2005-03-17
KR20010079551A (ko) 2001-08-22
NO20010292L (no) 2001-03-08
PL345627A1 (en) 2002-01-02
ATE288746T1 (de) 2005-02-15
EP1098639A1 (en) 2001-05-16
SK1012001A3 (en) 2001-08-06
JP2002521326A (ja) 2002-07-16
DK1098639T3 (da) 2005-06-13
EP1516617A2 (en) 2005-03-23
ES2237929T3 (es) 2005-08-01
SI1098639T1 (no) 2005-08-31
IL140664A0 (en) 2002-02-10
DE69923687T2 (de) 2006-04-06
EA200100165A1 (ru) 2001-08-27
AU5053799A (en) 2000-02-14
CN1310620A (zh) 2001-08-29
EP1098639B1 (en) 2005-02-09
CA2338211A1 (en) 2000-02-03
PT1098639E (pt) 2005-06-30
WO2000004890A1 (en) 2000-02-03
HUP0103199A2 (hu) 2002-05-29
TR200100207T2 (tr) 2001-05-21
HUP0103199A3 (en) 2002-08-28
AP2001002036A0 (en) 2001-03-31
OA11579A (en) 2004-06-01
ID26986A (id) 2001-02-22
HK1037865A1 (en) 2002-02-22

Similar Documents

Publication Publication Date Title
EE200200172A (et) Ühendid isheemia ravimiseks
HUP0202477A3 (en) Use of phthalazine derivatives
LV12666B (lv) Antipikornavirusu savienojumi to iegusana un lietosana
FI990171A0 (fi) Uusia yhdisteitä ja koostumuksia tryptaasiaktiivisuuden liittyvien tautien hoitamiseksi
IS6575A (is) Hýdroxýfenýl-píperidín-4-ýlíden-metýl-bensamíðafleiður til að meðhöndla sársauka
NO20022624L (no) Heterocyklo-alkylsulfonylderivater som anti- inflammatoriske/smertestillende midler
ID29966A (id) Sulfoniloksazolamina-sulfoniloksazolamina sebagai senyawa-senyawa aktif terapi
IL150187A0 (en) Novel forms of pravastatin sodium
NO20010292L (no) Anvendelse av glukose-opptaks-enhancer for redusering av apoptose
AU7104500A (en) Use of rafp to inhibit or prevent apoptosis
PT1178984E (pt) Derivados de 1-trifluorometil-4-hidroxi-7-piperidinilamimometilcromano
PT1001962E (pt) Producao de compostos avermectina
NO20025703D0 (no) Fremgangsmåte for fremstilling av vannfritt natriumperklorat
NO20010293D0 (no) Anvendelse av glukose-opptaks-enhancer for redusering av post- ischemi skade av hjertet
GB0130573D0 (en) Improvements to leg supports
GB0312566D0 (en) Veterinary composition for the topical treatment of traumatized or inflamed skin
PT1175417E (pt) Compostos substituidos de benzolactamas
GB0018054D0 (en) Improvements to ploughs
ID26666A (id) Penggunaan agen untuk pencegahan penyakit gusi
FR2778564B1 (fr) Utilisation de composes reduisant l'apoptose
FI981139A0 (fi) Normobarisen hypoksian käyttö terapeuttisesti
ZA996444B (en) Composition to enhance skin premeation of topical skin agents.
FI991138A0 (fi) Normobarisen hypoksian käyttö terapeuttisesti
TW407494U (en) Structural improvement of medial bed
IT1309424B1 (it) Soluzione veicolante per l'assorbimento transdermico di principiattivi farmacologici